EPSTEIN-BARR VIRUS EXPRESSION IN NORMAL HUMAN EPITHELIUM
正常人上皮中的 Epstein-Barr 病毒表达
基本信息
- 批准号:3177274
- 负责人:
- 金额:$ 19.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1984
- 资助国家:美国
- 起止时间:1984-12-01 至 1996-06-30
- 项目状态:已结题
- 来源:
- 关键词:B lymphocyte Burkitt's lymphoma Epstein Barr virus Herpesviridae disease athymic mouse cell differentiation epithelium gene deletion mutation gene expression genetic manipulation genetic markers genetic transcription host organism interaction human subject immunoelectron microscopy immunofluorescence technique latent virus infection microorganism immunology molecular cloning monoclonal antibody nasopharyngeal neoplasms nucleic acid hybridization nucleic acid probes nucleic acid sequence oncogenic virus oral mucosa polymerase chain reaction tissue /cell culture viral carcinogenesis virus DNA virus antigen virus cytopathogenic effect virus genetics virus infection mechanism virus replication
项目摘要
The long term goal of the proposed research is to identify viral and
cellular factors, unique to human mucosa, which contribute to
Epstein-Barr virus (EBV) pathogenesis and to mechanisms of persistence.
EBV-associated diseases point to the importance of viral interactions in
human mucosa: nasopharyngeal carcinoma and oral hairy leukoplakia.
(characterized by EBV latency and an aggressively replicative infection,
respectively) are epithelial cell diseases. African Burkitt's lymphoma,
with its unusual tissue distribution, is a malignancy of the
mucosal-associated lymphoid tissue. Utilizing information gained in the
current grant period which suggests for the first time the existence of
multiple EBV variants with distinct biologic differences and tissue
tropisms, we propose the following aims to reach our long-term goals: 1)
Determination of the molecular structure of lytic EBV; 2) Evaluation of
the distribution of transforming and lytic variants within epithelial and
lymphoid components of the mucosal system; 3) Elucidation of mechanisms
for EBV persistence in the epithelial components of the mucosa.
Based on the known biologic activity of a spontaneous laboratory
mutant deleted for the EBV nuclear antigen 2 (EBNA2) encoding gene, we
postulate that similar wild type variants represent the "missing link' in
our understanding of EBV pathogenic mechanisms. By molecular cloning and
polymerase chain reaction analysis, we will delineate (under aim 1) the
genetic structure of EBNA2 deleted virus taken directly from throat
washings, thus avoiding the selection bias inherent with passage in
lymphocyte culture. Demonstration of deletions and potential gene
rearrangements will provide an indication of altered biologic activity.
In aim #2, use of select genotypic markers amenable to PCR analysis will
allow us to track EBV variants through tissue compartments of the mucosal
system, identify tissue tropisms, and locate sites for potential
interaction between strains. Finally, we will use EBV strains, isogenic
except for their EBNA2 gene, to analyze in experimentally infected
epithelium transcription from EBV's putative transforming genes. In
infected human epithelial cell implants maintained in nude mice, we will
relate patterns of gene expression to the EBNA2 deletion mutant's ability
to sustain long-term infection in the absence of a viable B cell
component.
长期 拟议研究的目标是识别病毒,
细胞因子,人类粘膜特有的,有助于
EB病毒(EBV)的发病机制和持久性。
EB病毒相关疾病指出了病毒相互作用在
人粘膜:鼻咽癌和口腔毛状白斑。
(特征为EBV潜伏期和侵袭性复制感染,
分别)是上皮细胞疾病。 非洲伯基特淋巴瘤
其不寻常的组织分布,是一种恶性肿瘤,
粘膜相关淋巴组织。 利用在《公约》中获得的信息,
目前的赠款期间,这表明第一次存在的
具有明显生物学差异和组织学特征的多种EBV变异体
根据我们的取向,我们提出以下目标来实现我们的长期目标:1)
裂解性EBV的分子结构的测定; 2)裂解性EBV的分子结构的评价;
上皮内转化和裂解变体的分布,
粘膜系统的淋巴成分; 3)阐明机制
EB病毒在粘膜上皮成分中的持久性。
基于自发实验室的已知生物活性
缺失EBV核抗原2(EBNA 2)编码基因的突变体,我们
假设类似的野生型变异体代表了
我们对EB病毒致病机制的了解。 通过分子克隆,
聚合酶链反应分析,我们将描绘(根据目标1)
直接从咽喉中提取的EBNA 2缺失病毒的遗传结构
洗涤,从而避免选择偏见固有的通道,
淋巴细胞培养 缺失和潜在基因的证明
重排将提供改变的生物活性的指示。
在目标#2中,使用适合于PCR分析的选择基因型标记将
使我们能够通过粘膜的组织隔室追踪EBV变异体,
系统,识别组织向性,并定位潜在的
菌株间的相互作用 最后,我们将使用EBV毒株,
除了他们的EBNA 2基因,
上皮细胞从EBV的假定转化基因转录。 在
感染的人上皮细胞移植物在裸鼠中维持,我们将
将基因表达模式与EBNA 2缺失突变体的能力相关联
在缺乏存活B细胞的情况下维持长期感染
成分
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN W SIXBEY其他文献
JOHN W SIXBEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN W SIXBEY', 18)}}的其他基金
Epstein-Barr Virus-Enhanced Tumor Progression
Epstein-Barr 病毒增强的肿瘤进展
- 批准号:
7414860 - 财政年份:2006
- 资助金额:
$ 19.26万 - 项目类别:
Epstein-Barr Virus-Enhanced Tumor Progression
Epstein-Barr 病毒增强的肿瘤进展
- 批准号:
7247107 - 财政年份:2006
- 资助金额:
$ 19.26万 - 项目类别:
Epstein-Barr Virus-Enhanced Tumor Progression
Epstein-Barr 病毒增强的肿瘤进展
- 批准号:
7146318 - 财政年份:2006
- 资助金额:
$ 19.26万 - 项目类别:
DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS
爱泼斯坦巴尔病毒粘膜发病的决定因素
- 批准号:
6176107 - 财政年份:1996
- 资助金额:
$ 19.26万 - 项目类别:
DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS
爱泼斯坦巴尔病毒粘膜发病的决定因素
- 批准号:
2458673 - 财政年份:1996
- 资助金额:
$ 19.26万 - 项目类别:
DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS
爱泼斯坦巴尔病毒粘膜发病的决定因素
- 批准号:
2897144 - 财政年份:1996
- 资助金额:
$ 19.26万 - 项目类别:
DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS
爱泼斯坦巴尔病毒粘膜发病的决定因素
- 批准号:
2749379 - 财政年份:1996
- 资助金额:
$ 19.26万 - 项目类别:
DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS
爱泼斯坦巴尔病毒粘膜发病的决定因素
- 批准号:
2015466 - 财政年份:1996
- 资助金额:
$ 19.26万 - 项目类别:
Epstein Barr Virus Induced Genomic Instability
EB 病毒引起的基因组不稳定
- 批准号:
6881605 - 财政年份:1995
- 资助金额:
$ 19.26万 - 项目类别:
EPSTEIN-BARR VIRUS INDUCED GENOMIC INSTABILITY
爱泼斯坦-巴尔病毒引起的基因组不稳定
- 批准号:
2330935 - 财政年份:1995
- 资助金额:
$ 19.26万 - 项目类别:
相似海外基金
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
GSK3 抑制作为伯基特淋巴瘤的辅助治疗
- 批准号:
8653055 - 财政年份:2014
- 资助金额:
$ 19.26万 - 项目类别:
The role of activation-induced cytidine deaminase (AID) mediated DNA damage in the pathogenesis of Burkitt's Lymphoma
活化诱导胞苷脱氨酶 (AID) 介导的 DNA 损伤在伯基特淋巴瘤发病机制中的作用
- 批准号:
258438392 - 财政年份:2014
- 资助金额:
$ 19.26万 - 项目类别:
Research Fellowships
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
GSK3 抑制作为伯基特淋巴瘤的辅助治疗
- 批准号:
8788701 - 财政年份:2014
- 资助金额:
$ 19.26万 - 项目类别:
The interaction of Burkitt's lymphoma cofactors EBV and Plasmodium
伯基特淋巴瘤辅助因子 EBV 和疟原虫的相互作用
- 批准号:
8846480 - 财政年份:2012
- 资助金额:
$ 19.26万 - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7289830 - 财政年份:2006
- 资助金额:
$ 19.26万 - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7097879 - 财政年份:2006
- 资助金额:
$ 19.26万 - 项目类别:
REGULATION OF EBV TRANSCRIPTION IN BURKITT'S LYMPHOMA
伯基特淋巴瘤中 EBV 转录的调控
- 批准号:
7349162 - 财政年份:2006
- 资助金额:
$ 19.26万 - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7684750 - 财政年份:2006
- 资助金额:
$ 19.26万 - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7492826 - 财政年份:2006
- 资助金额:
$ 19.26万 - 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
- 批准号:
7935180 - 财政年份:2006
- 资助金额:
$ 19.26万 - 项目类别: